GYRE · Gyre Therapeutics Inc
United States · RS rating 34 · As of 2026-10-14
| Price | 6.47 USD |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 44 / 67 / 25 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 17 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -20.0% |
| Sales growth Q/Q | +21.7% |
| Distance from 52-week high | +27.1% |
| Market cap (USD) | $679.4M |